Corrigendum to "Drug development for Autism Spectrum Disorder (ASD): Progress, challenges, and future directions. [European Neuropsychopharmacology Volume 48, July 2021, Pages 3-31]"

Affiliations

¹ Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024, United States. Electronic address: jmccracken@mednet.ucla.edu.
² Department of Pediatrics, University of Toronto, Toronto, Canada.
³ Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Univesitario Gregorio Maranon, and School of Medicine, Universidad Complutense de Madrid, CIBERSAM, Madrid, Spain.
⁴ Duke University Medical Center, Durham, North Carolina, United States.
⁵ Yale Child Study Center, New Haven, Connecticut, United States.
⁶ Institute of Psychiatry, Psychology and Neuroscience, King's College De Crespigny Park, Denmark Hill, London SE5 8AF, United Kingdom.
⁷ Neuroscience Therapeutic Area, Janssen Research & Development, Pennington, New Jersey, United States.
⁸ Department of Psychiatry, Columbia University, New York, NY, United States.

Free article

Published Erratum

James T McCracken et al. Eur Neuropsychopharmacol. 2021 Sep.

Free article

. 2021 Sep:50:133-134.

doi: 10.1016/j.euroneuro.2021.07.090. Epub 2021 Aug 2.

¹ Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024, United States. Electronic address: jmccracken@mednet.ucla.edu.
² Department of Pediatrics, University of Toronto, Toronto, Canada.
³ Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Univesitario Gregorio Maranon, and School of Medicine, Universidad Complutense de Madrid, CIBERSAM, Madrid, Spain.
⁴ Duke University Medical Center, Durham, North Carolina, United States.
⁵ Yale Child Study Center, New Haven, Connecticut, United States.
⁶ Institute of Psychiatry, Psychology and Neuroscience, King's College De Crespigny Park, Denmark Hill, London SE5 8AF, United Kingdom.
⁷ Neuroscience Therapeutic Area, Janssen Research & Development, Pennington, New Jersey, United States.
⁸ Department of Psychiatry, Columbia University, New York, NY, United States.

No abstract available

Erratum for

Drug development for Autism Spectrum Disorder (ASD): Progress, challenges, and future directions.
McCracken JT, Anagnostou E, Arango C, Dawson G, Farchione T, Mantua V, McPartland J, Murphy D, Pandina G, Veenstra-VanderWeele J; ISCTM/ECNP ASD Working Group. McCracken JT, et al. Eur Neuropsychopharmacol. 2021 Jul;48:3-31. doi: 10.1016/j.euroneuro.2021.05.010. Epub 2021 Jun 19. Eur Neuropsychopharmacol. 2021. PMID: 34158222 Free PMC article. Review.